 |
|
|
| |
Analysis of Protocol-Defined Virologic Failure Through Week 96 From a Phase 2 Trial (P011) of Islatravir and Doravirine in Treatment-Naïve Adults WithHIV-1 Infection
|
| |
| |
Glasgow 2020 Oct 5-8 virtual
Reported by Jules Levin
C. Orkin1; J.-M. Molina2; Y. Yazdanpanah3; C. Chahin Anania4; J. Eron5; S.O. Klopfer6; A. Grandhi6; J.X. Xu6; K. Eves6; D. Hepler6; M.N. Robertson6; C. Hwang6; G.J. Hanna6; T. Correll6
1Queen Mary University of London, London, UK; 2Saint-LouisHospital and University, Department of Infectious Diseases, Paris, France; 3Bichat Hospital, Paris, France; 4Hospital Hernán Henríquez Aravena de Temuco, Temuco, Chile; 5Division of Infectious Diseases, University of North Carolina, Chapel Hill, NC, USA; 6Merck & Co., Inc., Kenilworth, NJ, USA
|
| |
|
|
|
|
|
